Medical genome doctrine governance

There is currently no formally recognized standalone Indian doctrine called the “Medical Genome Doctrine Governance.” Its principles can nevertheless be developed from constitutional privacy, bodily autonomy, medical ethics, genetic-data protection, informed consent, biotechnology regulation, patent law, and anti-discrimination principles.

The doctrine would govern how human genomic information is collected, tested, interpreted, stored, shared, researched, and used in medical decision-making. Because genomic information can reveal both present health conditions and future disease susceptibility, it presents unusually significant legal and ethical questions.

Meaning and scope

A medical genome refers to the genetic information contained within an individual's genome that may be relevant to diagnosis, disease susceptibility, treatment response, reproductive decisions, or medical research.

Medical genome governance would therefore cover:

• genetic testing and sequencing;
• genomic diagnosis;
• pharmacogenomics;
• cancer genomics;
• hereditary disease screening;
• genomic research;
• genomic databases;
• sharing of genetic information;
• genetic counselling; and
• clinical use of genomic algorithms.

The central governance principle should be that genomic information must remain subject to lawful authority, informed consent, scientific reliability, privacy safeguards, and accountable medical use.

Constitutional protection of genomic information

The most important Indian authority is Justice K.S. Puttaswamy (Retd.) v Union of India, (2017) 10 SCC 1.

The Supreme Court recognized privacy as a fundamental right under Article 21 and emphasized dignity, autonomy, bodily integrity, and informational privacy.

Genomic information fits particularly strongly within informational privacy because DNA can reveal highly personal information about an individual and potentially about biological relatives.

Accordingly, collection of genomic information should generally have a legitimate purpose and appropriate legal safeguards.

Genetic autonomy and informed consent

Genomic testing should ordinarily be based on meaningful informed consent.

In Samira Kohli v Dr Prabha Manchanda, (2008) 2 SCC 1, the Supreme Court recognized the importance of informed consent in medical treatment.

Applied to genomic medicine, consent should address the nature and purpose of the test and, where reasonably foreseeable, the possibility that testing may reveal:

• hereditary disease;
• future disease susceptibility;
• carrier status;
• information concerning biological relatives;
• unexpected findings; or
• information unrelated to the original medical purpose.

A patient's consent to medical treatment should not automatically be interpreted as unlimited authorization for unrelated genomic research or commercial exploitation.

Genomic privacy

Genomic information is difficult to treat as ordinary medical information because genetic characteristics may remain relevant throughout an individual's life.

A genomic database may potentially reveal relationships among individuals and information about family members who never personally consented to testing.

Therefore, governance should establish strict controls over:

• access;
• storage;
• disclosure;
• research use;
• cross-institutional transfers;
• commercial use; and
• cybersecurity.

The proportionality principles recognized in K.S. Puttaswamy v Union of India (Aadhaar), (2018) 1 SCC 809 are particularly relevant where large-scale genomic databases are established by public authorities.

Government genomic databases

Government genomic databases may have legitimate purposes such as disease research, identification of certain medical conditions, or public-health planning.

However, mass genomic collection raises constitutional concerns.

The government should demonstrate:

1. a lawful basis;
2. a legitimate objective;
3. necessity;
4. proportionality;
5. adequate security;
6. limited retention; and
7. safeguards against misuse.

The mere availability of genomic technology does not itself establish a legal justification for compulsory genomic collection.

Compulsory genomic testing

Compulsory genomic testing raises particularly serious questions concerning bodily autonomy and privacy.

The reasoning in Selvi v State of Karnataka, (2010) 7 SCC 263 is relevant by analogy. The Supreme Court emphasized personal liberty and protection against involuntary extraction of highly personal information.

Although Selvi concerned different investigative techniques, its principles support careful constitutional scrutiny of compelled extraction of biological or cognitive information.

A compulsory genomic-testing regime would therefore require a particularly strong legal justification and procedural safeguards.

Medical interpretation and scientific reliability

Genomic information does not automatically constitute a medical diagnosis.

A genetic variant may be:

• clearly pathogenic;
• probably pathogenic;
• of uncertain significance;
• benign; or
• clinically insignificant.

Healthcare professionals should therefore avoid presenting uncertain genomic findings as definite disease predictions.

Medical negligence principles become relevant when healthcare professionals improperly interpret genomic results or make unreasonable treatment decisions based upon unreliable genomic information.

In Jacob Mathew v State of Punjab, (2005) 6 SCC 1, the Supreme Court discussed professional negligence and the standard of reasonable medical care.

The same principle can apply to genomic medicine: clinicians should act according to an appropriate professional standard while recognizing the scientific uncertainty inherent in genomic interpretation.

Incidental genomic findings

Genomic testing may reveal information unrelated to the original reason for testing.

For example, a test undertaken for one medical condition may unexpectedly reveal susceptibility to another condition.

Governance must therefore determine when such information should be disclosed and whether the patient should have been informed beforehand about the possibility of incidental findings.

This strengthens the importance of pre-test genetic counselling and informed consent.

Family interests and genomic information

Genomic information creates an unusual conflict between individual privacy and familial medical interests.

A patient's genetic result may indicate that biological relatives face a potentially serious hereditary risk.

The legal system must therefore balance:

• the patient's confidentiality;
• the relative's potential interest in receiving medically significant information;
• professional confidentiality;
• prevention of serious harm; and
• applicable legal obligations.

There should not be an automatic rule that every relative has a right to access another person's genomic information. Disclosure should depend upon legally and ethically justified circumstances.

Genomic discrimination

Genetic information could potentially be misused by employers, insurers, financial institutions, or other organizations.

For example, a person with a genetic predisposition to a disease could face adverse treatment even though they are currently healthy.

Such practices raise concerns under constitutional equality and dignity principles.

Article 14 and Article 21 therefore provide an important foundation for preventing arbitrary discrimination based on genetic characteristics.

Genomic research

Research involving human genomes requires particularly careful governance.

Researchers should distinguish between:

• clinical treatment;
• observational research;
• genetic databases;
• population-level studies; and
• commercial genomic research.

Appropriate consent, ethical review, confidentiality, and security mechanisms should accompany research involving identifiable genomic information.

Where possible, researchers should use de-identified information while recognizing that genomic data can be difficult to completely anonymize.

Commercialization and genomic data

Modern genomic medicine creates significant commercial opportunities. Companies may use genomic datasets to develop diagnostics, medicines, algorithms, and personalized therapies.

Commercial utility, however, should not automatically override individual privacy.

The legal framework should clarify:

• who may access genomic data;
• for what purpose;
• whether secondary commercial use is permitted;
• what consent is required;
• how long information may be retained; and
• what protections exist against unauthorized disclosure.

Genomic patents and ownership

Patent law creates another dimension of genome governance.

In Association for Molecular Pathology v Myriad Genetics, Inc., 569 U.S. 576 (2013), the U.S. Supreme Court held that naturally occurring isolated DNA is not patent-eligible merely because it has been isolated, while synthetic DNA may receive different treatment.

Similarly, Diamond v Chakrabarty, 447 U.S. 303 (1980) addressed the patentability of human-made biological inventions.

These decisions illustrate an important distinction between naturally occurring biological information and human-created technological inventions.

They do not establish that an individual owns every legal right in their genome, but they demonstrate why genomic governance must distinguish personal genomic information from patentable biotechnology.

Governance of AI-based genomic medicine

Artificial intelligence may increasingly interpret genomic information and predict disease risks or treatment responses.

Governance should require:

• scientific validation;
• appropriate training data;
• transparency concerning limitations;
• monitoring for bias;
• human clinical oversight;
• cybersecurity;
• auditability; and
• mechanisms to correct erroneous results.

An AI-generated genomic prediction should not automatically be treated as medically conclusive.

Proportionality and genomic governance

Where genomic regulation interferes with privacy or bodily autonomy, proportionality becomes central.

Modern Dental College and Research Centre v State of Madhya Pradesh, (2016) 7 SCC 353 provides the general proportionality framework.

A genomic measure should therefore have:

• a legitimate objective;
• a rational connection to that objective;
• necessity;
• minimal impairment where appropriate; and
• a proportionate balance between public benefit and individual rights.

Relevant case laws

Important authorities for developing Medical Genome Doctrine Governance include:

• Justice K.S. Puttaswamy (Retd.) v Union of India, (2017) 10 SCC 1 — privacy, dignity and informational autonomy.
• K.S. Puttaswamy v Union of India, (2018) 1 SCC 809 — proportionality and informational privacy.
• Selvi v State of Karnataka, (2010) 7 SCC 263 — personal liberty and protection against involuntary extraction of highly personal information.
• Samira Kohli v Dr Prabha Manchanda, (2008) 2 SCC 1 — informed consent and medical autonomy.
• Jacob Mathew v State of Punjab, (2005) 6 SCC 1 — medical negligence and professional standards.
• Modern Dental College and Research Centre v State of Madhya Pradesh, (2016) 7 SCC 353 — proportionality.
• Association for Molecular Pathology v Myriad Genetics, Inc., 569 U.S. 576 (2013) — patentability of naturally occurring genetic material.
• Diamond v Chakrabarty, 447 U.S. 303 (1980) — patentability of human-made biological inventions.

Conclusion

Medical Genome Doctrine Governance can be understood as a proposed framework ensuring that genomic medicine develops within the boundaries of privacy, autonomy, informed consent, scientific reliability, equality, confidentiality, and responsible biotechnology governance.

Its central principle should be:

The ability to decode a person's genome does not eliminate that person's legal and constitutional interests in controlling how their genomic information is obtained, interpreted, shared, and used.

Indian constitutional jurisprudence, particularly Puttaswamy, Selvi, Samira Kohli, and Modern Dental College, provides a strong foundation for developing future genomic governance. As genomic medicine becomes more widespread, the law will increasingly need to balance the enormous public-health value of genomic information against the equally important rights of individuals to privacy, dignity, autonomy, and protection from misuse.